Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-10961276-B2
Publication Date
2021-03-30
Expiration Date
Abstract
The present disclosure is directed to a universal antivenom for the treatment of venomous animal bites, and methods of developing the same using a novel targeted phage display technique.
Core Innovation
The invention provides a multi-species antivenom composition that includes a phage-expressed peptide binding to a target common to more than one animal venom, together with a pharmaceutically acceptable carrier. The peptide is selected from SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, or any combination thereof. The disclosed embodiments focus on venom targets using consensus or semi-conserved target design from multiple snake venom sequences.
The disclosed peptide-based antivenom is based on short peptides expressed using M13 phage, where the peptides are 7–12 mers and may be linear or circular. The binding target is described as especially centered on phospholipase A2 (PLA2), including active and metal-binding sites, with the peptides selected to bind conserved venom targets common across multiple venoms. The document further describes sequence embodiments including inverse consensus peptides.
The document additionally discloses a diagnostic kit that uses peptide/label conjugates to identify venom species and venom severity, grounded on peptide-binding behavior of the claimed composition. Non-limiting example results are described in terms of phage clone selection that inhibits a portion of PLA2 activity and a representative clone showing cross-species anti-PLA2 activity across major North American crotalid venoms. The document also discusses improved manufacturing and safety concepts, including faster selection cycles and avoidance of serum sickness, and describes stability at ambient temperatures and relevant test concepts.
Claims Coverage
The independent claims are clm-00001 and clm-00006, covering a multi-species antivenom composition and the phage-expressed peptides themselves. Across the independent claims, the key inventive features emphasize phage-expressed peptides selected from specified SEQ ID NOs, binding to a common venom target or one or more animal venoms, and use of a pharmaceutically acceptable carrier in the composition claim.
Multi-species antivenom composition with phage-expressed peptide binding a common venom target
A multi-species antivenom composition comprising a phage-expressed peptide that binds to a target common to more than one animal venoms; and a pharmaceutically acceptable carrier, wherein the phage-expressed peptide is selected from SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, and any combination thereof.
Phage-expressed peptide binding to one or more animal venoms selected from specified SEQ IDs
A phage-expressed peptide that binds to a target in one or more animal venoms, wherein the peptide is selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, and any combinations thereof.
Overall, the claim coverage centers on specified short phage-expressed peptides that bind to conserved venom targets, including targets common to more than one animal venom in the composition claim.
Stated Advantages
Avoidance of serum sickness.
Faster selection cycles.
Stability at ambient temperatures.
Documented Applications
A diagnostic kit for venom species identification and venom severity using peptide/label conjugates based on the disclosed peptide-binding composition.
Interested in licensing this patent?